Home/Pipeline/TN-783

TN-783

Obesity / Metabolic Dysfunction

PreclinicalActive

Key Facts

Indication
Obesity / Metabolic Dysfunction
Phase
Preclinical
Status
Active
Company

About Tenvie Therapeutics

Tenvie Therapeutics is a private, preclinical-stage biotech with a specialized focus on central nervous system (CNS) drug development. The company leverages a validated, CNS-centric small molecule engine to create precisely engineered compounds that are either highly brain-penetrant or peripherally restricted, offering clinical development optionality. Its pipeline, initially acquired from Denali Therapeutics, targets NLRP3 inflammasome and other pathways, with early data showing promise in reversing hypothalamic inflammation and driving weight loss in obesity models. Led by a seasoned team of CNS drug developers, Tenvie is positioned to address high-need areas in neurology and metabolic diseases.

View full company profile